

Commercial/Healthcare Exchange PA Criteria

Effective: April 1, 2011

Prior Authorization: Cayston

Products Affected: Cayston (aztreonam) inhalation solution

Medication Description: Cayston (aztreonam) is an antibacterial drug. Cayston is bactericidal against Gram-negative aerobic bacteria by binding to penicillin-binding protein-3(PBP-3), which results in inhibition of bacterial cell wall synthesis and often results ultimately in cell lysis and death; filamentation also occurs in Enterobacteriaceae and *P. aeruginosa*; does not induce beta-lactamase activity, but has a high degree of stability in the presence of bacterial beta-lactamases; does not bind appreciably to any essential PBPs in gram-positive or anaerobic organisms

Covered Uses: Improve respiratory symptoms in cystic fibrosis (CF) patients with *Pseudomonas aeruginosa*.

Exclusion Criteria:

- A. Known hypersensitivity to aztreonam
- B. Patients with FEV1 <25% or >75% predicted
- C. Patients colonized with *Burkholderia cepacia*

Required Medical Information:

- 1. Diagnosis
- 2. Sputum culture results

Age Restrictions: 7 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 6 months

Other Criteria:

- A. Patient has a diagnosis of cystic fibrosis; AND
- B. Patient has a positive sputum culture for *P. aeruginosa*; AND
- C. Patient has FEV1 > 25% and < 75%; AND
- D. Patient is not colonized with *Burkholderia cepacia*.

References:

- 1. CAYSTON(R) inhalation solution, aztreonam inhalation solution. Gilead Sciences, Inc., Foster City, CA, 2010.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	2/2011
2	Update	Moved to updated template Added exclusion criteria: known sensitivity to aztreonam, patients with FEV1 <25% or >75% predicted, patients colonized with Burkholderia cepacia	All	2/2020